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Abstract
Direct tumor injections of oligonucleotides containing
unmethylated CpGmotifs (CpGODN) intomurine colon
tumor 26 (CT-26) tumors can induce a potent antitumor
response. Tumor size at the beginning of treatment
determines the final therapeutic outcome, with smaller
tumors responding favorably to CpG ODN therapy
whereas large tumors do not. CpG ODN injections in
small tumors resulted in tumor necrosis and extensive
inflammatory cell infiltration, with average survival that
is significantly higher (48.1 ± 34 days) when compared
to control ODN–treated mice (16.1 ± 3.5 days). Cyto-
kines and chemokines are expressed at different levels
in small and large CT-26 tumors following intratumoral
injections of CpGODN.We observed that granulocyte–
macrophage colony-stimulating factor and interleukin
(IL) 6 are the major cytokines that were overexpressed
in CpG ODN–treated small tumors but not in large
tumors. Similarly, several chemokines (CXCL1, CCL2,
and CCL3) were also significantly higher in CpG ODN–
treated small tumors compared to control ODN–treated
tumors.
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Introduction
The stimulation of the immune system, which can overcome
tumor-mediated immune suppression, may be an effective
therapy against cancer. Oligonucleotides containing unme-
thylated CpG motifs (CpG ODN) stimulate vertebrate im-
mune cells in vitro and clinical trials are currently underway
for evaluation of CpG therapies for cancer, allergy, and
infectious disease [1]. CpGODNs are recognized by pattern
recognition receptors, a family of receptors known as Toll-
like receptors (TLRs) [2]. The CpG ODNs are endocytosed
and there they meet their pattern recognition receptor,
TLR-9, which is an intracellular receptor [3]. Upon recogni-
tion of CpG, TLR-9 recruits the adaptor molecule, myeloid
differentiation factor 88 (MyD88), through a common path-
way of Toll with interleukin (IL) 1R domains. Subsequent
downstream signaling involves IL-1R–associated kinases
(IRAK1) and tumor necrosis factor a (TNF-a) receptor–asso-
ciated factor 6 (TRAF6). Further activation of NF-kB and c-Jun
NH2 terminal kinase (JNK) results in transcription from various
cytokines and chemokines genes [4]. TLR-9 field is relatively
young and, so far, a limited number of differences have been
noted between mice and humans. In mice, TLR-9 is expressed
on all myeloid cells, dendritic cells, and B cells, whereas in
humans, TLR-9 is only expressed on antigen-presenting cells,
B cells, and neutrophils [5].
We had hypothesized that manipulation of the tumor micro-
environment by introducing immune-stimulating CpG ODNs
directly into the tumors might result in an antitumor immune
response. This therapy is a form of immunization that uses the
in situ tumor as a source of antigen and introduces CpG ODN
as an adjuvant to activate an immune response within the
tumor. We refer to this as in situ immunization and it has been
shown in animal models that in situ immunization with biologic
response modifiers (BRMs) like granulocyte–macrophage col-
ony-stimulating factor (GM-CSF) and IL-12 [6] or IL-2 [7] can
induce tumor regression and stimulate systemic immunity.
Clinical studies from our group have also shown that intra-
tumoral injections of GM-CSF lead to tumor regression [8].
There are already reports in the literature of CpG stimulating an
antitumor response in experimental models [9,10]. We have
shown that directly injecting CpG into the tumor results in an
antitumor response [11], whereas it was reported that peritu-
moral injections of CpG ODN were therapeutic for small tumors
but not for larger tumors [12].
There is a dynamic relationship between tumor cells, in-
flammatory cells, cytokines, and chemokines [13]. Cytokines
and chemokines within tumors can contribute to the progres-
sion of tumors to a more aggressive metastatic phenotype or
play a role in tumor therapy [14,15]. The pattern and kinetics of
cytokine/chemokine production can be greatly affected by CpG
ODNs. The splenic mRNA levels of IL-6, IL-12, and IL-1b, and
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of serum IL-6, IL-12, MIP-1b, and MCP-1 levels increase
significantly following intraperitoneal (i.p.) injections of CpG
ODN [16], although intramuscular injection of CpG induced
the expression of genes coding for chemokines in myocytes
[17]. In vitro studies also demonstrate that macrophage
exposed to CpG ODN upregulates expression of mRNA
encoding the chemokines MIP-1a, MIP-1b, MIP-2, RANTES,
MCP-1, and IP-10 [18]. We hypothesize that CpG ODN
injection into tumors might change the patterns of cytokines
and chemokines within the tumor microenvironment, con-
tributing to an antitumor response.
It is argued that cancer therapies might only be effective
against a low tumor burden. Tumor size determines the
antitumor activity of cisplatin or 5-fluorouracil, with de-
creased antitumor activity against large CT-26 tumors [19].
Larger CT-26 tumors were also resistant to peritumoral
injections of CpG ODN [12]. Similarly, intratumor injections
of IL-2 in murine mesothelioma were therapeutic in small
tumors but not in larger ones [7]. The present study inves-
tigates whether the antitumor effects of intratumoral injec-
tions of CpG ODN were affected by tumor size. This study
also provides quantitative changes in cytokine and chemo-
kine within the tumor microenvironment and in the serum
following direct tumor injection of CpG ODN.
Materials and Methods
Mice and Tumor Cell Lines
Female Balb/c mice, 4 to 6 weeks old, were used in the
study. All mice were kept according to IACUC guidelines
at the animal facility of SUNY at Buffalo. The mice were
checked daily and tumors measured three times a week. Co-
lon tumor 26 (CT-26), a colon carcinoma tumor, and Line-1,
an adenocarcinoma of Balb/c origin, were used for the pre-
sent study. CT-26 and Line-1 tumor cell lines were obtained
from ATCC (Manassas, VA) and were maintained in RPMI
1640 media supplemented with 10% fetal calf serum, antibi-
otic–antimycotic solution, and mercaptoethanol at 37jC and
5% CO2 (vol/vol). For implantation of tumor cells, adherent
tumor cells were trypsinized and resuspended in phosphate-
buffered saline (PBS), and 5  105 cells were implanted into
the subcutaneous sites in the right flank of the mice. For
the study of memory immune response, 5  105 CT-26
tumor or Line-1 adenocarcinoma cells were injected on the
left flank of the animal.
Reagents
CpG ODNs were a gift from Coley Pharmaceuticals
(Wellesley, MA). Immunostimulatory sequence of CpG
ODN 1826 (5V-TCCATGACGTTCCTGACGTT-3V) and con-
trol nonstimulatory sequences ODN 1982 (5V-TCCAGGA-
CTTCTCTCAGGTT-3V) were used in the present study. CpG
ODNs were phosphorothioate-modified and endotoxin-free.
Animal Experiments
Groups of mice were implanted with CT-26 tumor cells.
Tumors were allowed to grow until appropriate tumor size
was reached. The tumor size varied from 10 to 32 mm3
for small tumors and from 120 to 450 mm3 for large tu-
mors. Treatment consisted of daily intratumoral injections of
a 10-mg dose of CpG ODN or control ODN in 0.1 ml of sterile
PBS. Tumor size was measured three times a week with a
Vernier caliper and tumor volume [(short arm)2 long arm/2]
was calculated in cubic millimeters. The formula: tumor
growth rate = [(final tumor size  initial tumor size)/number
of days] was applied to determine tumor growth kinetics.
Data are reported in the form of either percent survival or
tumor growth rate.
Histology of Tumors Treated with CpG ODN or Control ODN
Small and large tumors were treated with CpG ODN or
control ODN for 5 days followed by surgical excision of
tumor. Tumors were fixed in 10% buffered formalin and
embedded in paraffin blocks for serial sectioning. Tumor
sections were stained with hematoxylin–eosin and exam-
ined for changes in histology.
Cytokines and Chemokines Quantification in Tumor Micro-
environment or in Serum
The tumor was surgically removed and a tumor extract
was prepared in T-per extraction buffer (Pierce, Rockland, IL)
supplemented with protease inhibitor cocktail (Pierce). Ten
milliliters of buffer was used per gram of tumor sample.
Supernatant was kept frozen at 80jC until analyzed. Blood
was taken from the animal and serum sample was kept in
80jC until analyzed. Levels of cytokines and chemokines
in tumor extract and in serum were analyzed by the Luminex-
100 flow cytometry assay. A total of 15 cytokines/chemokines
was monitored, namely, IL-1b, IL-2, IL-3, IL-4, IL-6, IL-10,
IL-12, G-CSF, GM-CSF, IFN-g, TNF-a, MCP-1 (CCL2), MIP-
1a (CCL3), KC (CXCL1), and RANTES (CCL5).
Statistics
All experiments were done in, at least, triplicate and
statistical significance of data was determined using a two-
tailed Student’s t test.
Results
Tumor Size at the Beginning of Treatment Determines the
Final Therapeutic Outcome
We have earlier shown that direct tumor injections of low
doses of CpG can result in slower tumor growth of estab-
lished B-16 melanoma and CT-26 murine tumors [11]. It was
also reported that peritumoral injection of CpG ODN was
found to be effective against small tumors but not against
larger tumors [12]. The aim of the present experiment was to
determine if antitumor effects of intratumoral injections of
CpG ODN were influenced by the tumor size. Animals were
divided into two groups depending on tumor size. Mice with
small tumors (average tumor size 15–20 mm3) were treated
with daily intratumoral injections of either CpG ODN or con-
trol ODN. In the other group, treatment began when the tu-
mor size was 125 to 140 mm3. The dose of CpG ODN (10 mg
per injection) used in the study was chosen as our results
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indicated no difference in the therapeutic response at lower
doses of CpG ODN (10–20 mg per injection), whereas at
higher doses (50 mg per injection or higher), overt signs of
toxicity were observed, which includes lethargy, weight loss,
and rough coat. Treatment continued until the tumor was
completely regressed or tumor burden became greater than
1500mm3. Mice whose tumors grew slowly were followed for
90 days for calculations of mean survival and tumor growth
rate. Mice whose tumors regressed were followed beyond
90 days and were used to determine immune memory.
In the group of CpG ODN–treated mice with small
tumors (n = 16), the average survival was significantly
higher (48.1 ± 34 days) when compared to 16.1 ± 3.5 days
for mice with small tumors treated with control ODN (n = 13,
P < .001) (Figure 1). The average survival of mice with small
tumors treated with CpG ODN was also significantly higher
than the average survival of 13.8 ± 4.7 days for large tu-
mor–bearing mice (n = 5) treated with CpG ODN (P < .001).
We saw no therapeutic effect of CpG ODN injections into
large tumors (Figure 2). This clearly demonstrates that
tumor size at the beginning of CpG ODN immune therapy
can determine the final therapeutic outcome, with smaller
tumors responding favorably to CpG ODN therapy whereas
large tumors do not.
Daily CpG ODN injections resulted in complete tumor
regression in 37% (6/16) of treated mice bearing small
tumors. No tumor regression was observed in large tumors
treated with CpG ODN, or in small or large tumors treated
with control ODN. Similarly, the average tumor growth rate
was significantly lower in CpG ODN–treated small tumors
(25.34 ± 31 mm3/day) compared to 59.5 ± 26.9 mm3/day in
control ODN–treated small tumors (P < .01). The average
tumor growth rate in CpG ODN–treated large tumors was
not significantly different from tumor growth rate in control
ODN–treated large tumors (Figure 3). Our earlier results of
direct tumor injections of PBS [11] were similar to results
obtained with control ODN and served as an additional
control (data not shown).
Histology
To investigate the changes induced by CpG ODN injec-
tions, a histologic analysis of tumors was done. Tumors were
treated with either CpG ODN or control ODN for 5 days.
Histologic evaluation of control ODN–treated tumors looked
like untreated tumors: a solid carcinoma with a high mitotic
index and no lymphocyte infiltration. The CpG ODN intra-
tumor therapy in small tumors produced areas of extensive
necrosis with lots of tumor-infiltrating lymphocytes and poly-
morphonuclear cells, whereas no lymphocyte infiltration and
necrosis were observed in CpG ODN–treated large tumors.
Treatment with CpG Induces a Memory Immune Response
in CT-26 Tumor
To investigate whether CpG ODN–mediated tumor re-
gression induced a memory immune response following
complete tumor regression, long-term surviving animals that
remained tumor-free for more than 4 months were implanted
with a lethal dose (5  105) of CT-26 cells in the left flank.
No tumor grew in any of the six long-term survivors, showing
Figure 1. Mice with small CT-26 tumors were treated with daily intratumoral
injections of either CpG ODN or control ODN. Figure shows the survival of
mice following treatment. Longer survival and tumor regression were seen in
small tumors treated with intratumor CpG ODN therapy.
Figure 2. Mice with large CT-26 tumors were treated with daily intratumoral
injections of either CpG ODN or control ODN. Figure shows the survival of
mice following treatment. Survival was not significantly different in CpG
ODN– or control ODN– treated groups. This shows that CpG ODN treatment
had no therapeutic effect in large tumors.
Figure 3. Mice with small or large CT-26 tumors were treated with daily
intratumoral injections of either control ODN or CpG ODN. Figure shows the
average tumor growth rate (mm3/day) following treatment. Small tumors
treated with CpG ODN show slower tumor growth compared to other groups,
which is consistent with longer survival and tumor regression, whereas higher
tumor growth rate in other groups is consistent with their therapeutic outcome
of no tumor regression and shorter survival.
Cytokines and Chemokines Following Injections of CpG ODN Sharma et al. 525
Neoplasia . Vol. 6, No. 5, 2004
that a memory immune response can be induced by intra-
tumoral injections of CpG ODN. To further determine the
specificity of the memory response, long-term survivors who
rejected the CT-26 rechallenge were subsequently injected
with a lethal dose (5  105) of Line-1 adenocarcinoma. All
six mice developed Line-1 adenocarcinoma tumors, indicat-
ing that the protective memory immune response resulting
from the direct tumor injection of CpG ODN is tumor-specific.
Changes in the Expression of Cytokines and Chemokines
in Mice with Small Tumors Following Intratumor Injections
of Either CpG ODN or Control ODN
To further investigate differences between small and
large tumors, we assayed soluble factors within the tumor
microenvironment before and after CpG ODN intratumor
therapy. A Luminex-100 bead assay was used to monitor
the expression of 15 soluble cytokines and chemokines in
the tumor microenvironment. Mice with small tumors (14–28
mm3) had their tumor injected with either CpG ODN or
control ODN for 3 days followed by analysis of soluble factors
within tumors and in serum.
Table 1 summarizes the significant differences in cytokine
and chemokine levels in both the tumor microenvironment
and in the serum of mice with small tumors. In CpG ODN–
treated tumors, intratumor levels of IL-6 and GM-CSF were
higher by 40-fold (P < .05) and 13-fold (P < .05), respec-
tively. Although G-CSF increased by 11-fold, it was not
significant due to a high standard deviation. Levels of IL-1b
and INF-gwere slightly but not significantly elevated following
intratumor injections of CpG ODN, whereas IL-2, IL-10, and
TNF-a were slightly but not significantly lower. No change in
the levels of expressions was observed for other cytokines.
The CpG ODN injections in small tumors also resulted in
significantly higher levels of several chemokines (Table 1).
Intratumoral expression of CXCL1 (KC) was more than
88-fold higher in CpG ODN–treated tumors (P < .05).
Levels of CCL2 (MCP-1) and CCL3 (MIP-1a) were higher
by 16-fold (P < .05) and 2-fold (P < .05), respectively. The
expression of CCL5 (RANTES) increased 1.8-fold and it
was only marginally significant (P > .05).
Changes in the levels of cytokines and chemokines in the
serum were also analyzed. Serum levels of IL-6, CXCL1,
CCL2, and CCL5 were significantly higher after treatment
with CpG ODN (Table 1). CCL5 was only found in the
serum after CpG ODN treatment, whereas levels of IL-6
and CXCL1 showed an eight-fold (P < .01) and a seven-fold
(P > .05) higher expression compared to mice in control
ODN–treated group. IL-10 was present in the serum of
some of the CpG ODN–treated mice but not in the serum
of any control ODN–treated mice.
Changes in the Expression of Cytokines and Chemokines
in Large Tumors After Intratumor Injections of CpG ODN
or Control ODN
Mice with large tumors (270–455 mm3) had their tumor
injected with either CpG ODN or control ODN for 3 days
followed by analysis of cytokines and chemokines in the
intratumor microenvironment and in the serum. In the tumor,
CCL5 (RANTES) was the only factor that was significantly
higher after CpG ODN treatment (Table 2). The intratumoral
level of CCL5 was higher by three-fold (P < .05). Intratumoral
levels of GM-CSF and G-CSF were more than 13-fold and
2-fold higher after CpG ODN treatment, but they were not
significant due to high standard deviations. We also found
marginally higher expressions of CCL2 (P > .05) and CCL3
(P > .05) in CpG ODN–treated mice. Unlike in small tumors,
CpG ODN did not stimulate IL-6, GM-CSF, or CXCL1
expression. CCL5 was also present in serum of CpG
ODN–treated mice, whereas no CCL5 could be detected
in serum of mice treated with control ODN. No significant
difference in the serum levels of other cytokines and chemo-
kines was observed following intratumor injections of large
tumors.
Discussion
Systemic administration of cytokines and BRMs such as
IL-2, TNF-a, GM-CSF, IL-12, or CpG ODN can induce an
antitumor response and activate protective immunity. How-
ever, systemic administrations of high doses of BRMs are
often associated with toxic side effects, preventing the use of
curable doses. One possible way of increasing the thera-
peutic index of BRMs is to use low-dose regional treatment,
like peritumoral or intratumoral injection. Intratumoral injec-
tions of IL-2 [7] or IL-12 [20] can induce local and systemic
antitumor immunity. Regional CpG injections are effective
against mouse neuroblastoma [9] and intracranial gliomas
Table 2. Key Cytokine and Chemokine Changes (pg/ml) in the Tumor
Microenvironment and in the Serum of Large Tumor-Bearing Mice Following
Treatment with Either Control ODN or CpG ODN.
Control
Mice
CpG-Treated
Mice
Fold
Increase
P
CCL5 Intratumor 723 ± 344 2361 ± 884 3 0.04
Serum 0 34 ± 6 nd
nd, not determined.
Table 1. Key Cytokine and Chemokine Changes (pg/ml) in the Tumor
Microenvironment and in the Serum of Small Tumor-Bearing Mice Following
Treatment with Either Control ODN or CpG ODN.
Control
Mice
CpG-Treated
Mice
Fold
Increase
P
IL-6 Intratumor 69 ± 46 2807 ± 1836 40 0.02
Serum 3 ± 3 24 ± 6 8 0.008
GM-CSF Intratumor 3.5 ± 0.57 46.75 ± 32.3 13 0.03
Serum 0 0 nd
CXCL1 Intratumor 38 ± 31 3379 ± 1436 88 0.02
Serum 12 ± 10 86 ± 68 7 0.07
CCL2 Intratumor 560 ± 413 8962 ± 3344 16 0.002
Serum 71 ± 22 159 ± 38 2 0.009
CCL3 Intratumor 988 ± 114 2343 ± 974 2 0.03
Serum 543 ± 370 1050 ± 246 1.9 0.09
CCL5 Intratumor 917 ± 393 1709 ± 565 1.8 0.06
Serum 0 70 ± 8 nd
nd, not determined.
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[10]. We have also found that intratumoral injections of low
doses of CpG ODN can result in a slower tumor growth rate
of murine CT-26 and B-16 tumors [11].
Tumor burden or tumor size can be a factor in the
outcome of a cancer immune therapy. A CpG ODN immune
therapy was shown to be effective against a relatively small
tumor, whereas larger CT-26 tumors were resistant [12]. IL-2
intratumor injections induced regression of small murine
mesothelioma tumors, whereas large tumors failed to re-
spond [7]. To determine if the antitumor effects of intra-
tumoral injections of CpG ODNs were dependent on the
tumor size, we compared intratumoral injections of CpG
ODN in small versus large tumors. Injections of 10 mg of
CpG ODN into small tumors significantly inhibited tumor
growth, increased survival, and resulted in the complete
tumor regression of established tumors in 37% of treated
mice, whereas CpG ODN treatment of large tumors was
completely ineffective.
The pattern and kinetics of cytokine production can be
greatly affected by CpGODNs. The antitumor effects of CpG
ODN are likely to be mediated by a series of events. First,
CpG ODN induces TLR-9–mediated release of local cyto-
kines and chemokines, which might directly affect tumors
cells and recruit inflammatory cells to the site of injection [18].
Intramuscular injection of CpG induced the expression of
genes coding for chemokines and MHC class II molecule on
myocytes [17], whereas in vitro studies also demonstrate
that macrophage exposed to CpG ODN upregulates expres-
sion of mRNA encoding the chemokines MIP-1a, MIP-1b,
MIP-2, RANTES, MCP-1, and IP-10 [18]. Consistent with
the induction of an inflammatory response after CpG ODN
treatment, we observed that small tumors become infiltrated
with neutrophils. The continued injections of CpG ODN
following infiltration of inflammatory cells into the tumor can
further change the cytokine profile in the tumor microenvi-
ronment as infiltrating cells respond to the CpG. Although
there are some in vitro studies showing secretion of certain
cytokines and chemokines following CpG ODN exposure
[16], no quantitative in vivo data were available for intratumor
response.
We found that CpG ODN injections resulted in significant
increases in the intratumor levels of GM-CSF and IL-6 in
small tumors, whereas injections into large tumors failed to
produce any significant changes in the cytokine expressions.
GM-CSF levels were significantly higher within small tumors
and in serum following CpG ODN treatment. There are
several ways that GM-CSF might induce an antitumor re-
sponse: it stimulates the tumor-lytic activity of cells of the
monocyte lineage [21,22], and it also attracts and activates
dendritic cells, which can increase the presentation of tumor
antigens [23]. In addition, receptors for GM-CSF are also
found on endothelial cells, stromal cells, fibroblasts, and
tumor cells, so GM-CSF might directly affect nonlymphoid
cells within the tumor.
IL-6 levels were also significantly higher in both tumors
and serum after CpG ODN injections into small tumors. CpG
ODN injection into small tumors results in a 40-fold increase
in the intratumor levels of IL-6. IL-6 is also a pleiotropic
cytokine and it can influence antigen-specific immune
responses and the inflammatory reaction. The transfection
of murine tumor cells with a functional IL-6 gene has been
shown to lead to the rejection of the genetically modified cells
by syngeneic hosts with the antitumor effects of IL-6 depen-
dent on the presence of GM-CSF [24]. Cross-linking of Toll-
like receptors can result in the secretion of IL-6, which can
block the immune-suppressive effects of regulatory CD4+
CD25+ T cells, allowing activation of the adaptive immune
response [25]. The induction of this cytokine, along with GM-
CSF, creates a permissive cytokine environment for immune
activation.
Chemokines can modulate tumor growth by three impor-
tant mechanisms: regulation of tumor-associated angiogen-
esis, activation of host antitumor response, and direct
stimulation of tumor cell proliferation [26]. Expressions of
several chemokines were significantly higher in small tumors
following intratumor injections of CpG ODN. Levels of CCL2
(MCP-1), CCL3 (MIP-1a), and CXCL1 (KC) significantly
increased, whereas no significant changes were observed
in large tumors. CXCL1 levels showed the greatest change,
increasing by more than 88-fold within CpG ODN–treated
small tumors compared to only a two-fold increase in large
tumors. Monocytes, macrophages, and vascular endothelial
cells can produce CXCL1, and are involved in neutrophil
chemotaxis and activation. In a classic microbial infection,
neutrophils are the first immune cells to arrive at the site of
infection where they quickly release antimicrobial products
and proinflammatory cytokines. CpG ODN injections mimic
microbial infections in that the unmethylated CpG ODN can
act like the unmethylated CpG motifs in prokaryotic DNA.
Consistent with increased level of CXCL1, the predominant
tumor-infiltrating cells we see early in theCpGODN treatment
of small tumors are neutrophils. Neutrophils express TLR-9,
which is the pattern recognition receptor for CpG motifs [27],
and cross-linking TLR-9 on neutrophils might stimulate an-
other cascade of cytokine and chemokine expression.
CCL2 was also significantly higher in CpG ODN–treated
small tumors. CCL2 specifically attracts monocytes, memory
T cells, and NK cells in vitro and activates tumoricidal
activities of macrophage in vivo. Although we did not see
significant numbers of these cells infiltrating tumors after
5 days of CpG ODN injections, later time points are being
assayed to determine whether CCL2 expression will even-
tually recruit these cells.
Because small tumors respond to CpG intratumor therapy
whereas larger tumors do not, this might be a clinically
relevant model as some patients’ tumors respond to immune
therapies whereas others do not. It would be interesting to
know if the cytokines and chemokines that are induced in
small, regressing tumors are also expressed in regressing
tumors in other animal models of cancer therapy. Addition-
ally, are these patterns of soluble factor expression also
shown in regressing human tumors during immune therapy?
If so, they may represent new therapeutic targets.
In conclusion, we have found that CpG ODN had sig-
nificant antitumor and systemic immune stimulatory proper-
ties including tumor-specific protective memory immune
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responses, but there may be limitations on the therapy
depending on tumor size or tumor burden. Although the
exact molecular mechanisms of the antitumor effects of
CpG ODN are still not known, data from our present study
demonstrate that overexpression of chemokines, notably
CXCL1 and CCL2, and cytokines GM-CSF and IL-6, coupled
with neutrophils infiltration, might be involved in CpG ODN–
mediated tumor regression. Further studies are currently
underway to correlate the temporal appearance of soluble
factors with changes in the tumor histology and the appear-
ance and activation of tumor-infiltrating inflammatory cells.
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